Exhibit 4.1


 


NEITHER THE ISSUANCE AND SALE OF THE SECURITIES
REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR (B) AN OPINION OF COUNSEL SELECTED BY THE HOLDER, IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION
IS NOT REQUIRED UNDER SUCH ACT, OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SUCH ACT. NOTWITHSTANDING THE FOREGOING,
THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A FINRA REGISTERED BROKER/DEALER OR OTHER LOAN
OR FINANCING ARRANGEMENT WITH AN “ACCREDITED INVESTOR” SECURED BY THE SECURITIES.


 


MEDICINE MAN TECHNOLOGIES, INC.


Warrant To Purchase Common Stock


 


Warrant No.: LEN-1


Number of Shares of Common Stock: 1,500,000


Date of Issuance: February 26, 2021 (“Issuance
Date”)


 


Medicine Man Technologies,
Inc., a Nevada corporation d/b/a Schwazze (the “Company”), hereby certifies that, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, SHWZ ALTMORE, LLC, the registered holder hereof or its permitted
assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at
the Exercise Price (as defined below) then in effect, at any time or times on or after the date hereof, but not after 11:59 p.m.,
New York time, on the Expiration Date, 1,500,000 fully paid nonassessable shares of Common Stock, all subject to adjustment as
provided herein (the “Warrant Shares” and, together with this Warrant (as defined below), collectively, the
“Securities”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock
(including any Warrants to purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”),
shall have the meanings set forth in Section 14. This Warrant is one of the Warrants to purchase Common Stock (the “Loan
Warrants”) issued pursuant to Section 4.01(b) of the Loan Agreement, dated as of February 26, 2021, by and among the
Company, as guarantor, the borrowers party thereto, the collateral agent, and SHWZ Altmore, LLC, a Delaware limited liability company,
as lender (as amended, the “Loan Agreement”).


 


 


 


 


 






    	 	1	 



     


    

 


 1. EXERCISE OF WARRANT.




 


(a) Mechanics of Exercise.
Subject to the terms and conditions hereof, this Warrant may be exercised by the Holder at any time or times on or after the Issuance
Date, in whole or in part, by (i) delivery of a written notice, in the form attached hereto as Exhibit A (the “Exercise
Notice”), of the Holder’s election to exercise this Warrant and (ii) payment to the Company of an amount equal
to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate
Exercise Price”) in, at the option of the Holder as expressed in the Exericse Notice, either (x) cash by wire transfer
of immediately available funds or (y) payment in accordance with Section 1(e) below. The Holder shall not be required to deliver
the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice with respect to less
than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant
evidencing the right to purchase the remaining number of Warrant Shares. Execution and delivery of an Exercise Notice for all of
the then-remaining Warrant Shares shall have the same effect as cancellation of the original of this Warrant after delivery of
the Warrant Shares in accordance with the terms hereof. On or before the first Trading Day following the date on which the Company
has received the Exercise Notice, the Company shall transmit by electronic mail an acknowledgment of confirmation of receipt of
the Exercise Notice to the Holder and the Company’s transfer agent (the “Transfer Agent”). On or before
the third Trading Day following the date on which the Company has received the Exercise Notice and the Aggregate Exercise Price,
the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”)
Fast Automated Securities Transfer Program and the Warrant Shares are subject to an effective resale registration statement in
favor of the Holder, credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to
the Holder’s or its designee’s balance account with DTC through its Deposit / Withdrawal At Custodian system, or (Y)
if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program or the Warrant Shares are not
subject to an effective resale registration statement in favor of the Holder, issue and dispatch by overnight courier to the address
as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder
or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise. The Company shall
be responsible for all fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant
Shares via DTC, if any. Upon delivery of the Exercise Notice and the Aggregate Exercise Price, the Holder shall be deemed for all
corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised,
irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates
evidencing such Warrant Shares, as the case may be. If this Warrant is submitted in connection with any exercise pursuant to this
Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of
Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than three
Trading Days after any exercise and at its own expense, issue a new Warrant (in accordance with Section 5(d)) representing the
right to purchase the number of Warrant Shares issuable immediately prior to such exercise under this Warrant, less the number
of Warrant Shares with respect to which this Warrant is exercised. No fractional Warrant Shares are to be issued upon the
exercise of this Warrant, but rather the number of Warrant Shares to be issued shall be rounded up to the nearest whole number.
The Company shall pay any and all transfer, stamp, issuance and similar taxes which may be payable with respect to the issuance
and delivery of Warrant Shares upon exercise of this Warrant.


 


(b) Exercise Price.
For purposes of this Warrant, “Exercise Price” means $2.50 per share, subject to adjustment as provided herein.


 


(c) Disputes.
In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the number of Warrant Shares,
the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance
with the terms of this Warrant.


 


 


 


 






    	 	2	 



     


    

 


(d) Insufficient Authorized
Shares. If at any time while this Warrant remains outstanding the Company does not have a sufficient number of authorized and
unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise of this Warrant at least a number
of shares of Common Stock equal to 100% of the number of shares of Common Stock as shall from time to time be necessary to effect
the exercise of all of this Warrant then outstanding (the “Required Reserve Amount” and the failure to have
such sufficient number of authorized and unreserved shares of Common Stock, an “Authorized Share Failure”),
then the Company shall immediately take all action necessary to increase the Company’s authorized shares of Common Stock
to an amount sufficient to allow the Company to reserve the Required Reserve Amount for this Warrant then outstanding. Without
limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share
Failure, but in no event later than 60 days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting
of its stockholders for the approval of an increase in the number of authorized shares of Common Stock. In connection with such
meeting, the Company shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders’
approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders
that they approve such proposal. Notwithstanding the foregoing, if any such time of an Authorized Share Failure, the Company is
able to obtain the written consent of a majority of the shares of its issued and outstanding shares of Common Stock to approve
the increase in the number of authorized shares of Common Stock, the Company may satisfy this obligation by obtaining such consent
and submitting for filing with the Securities and Exchange Commission an Information Statement on Schedule 14C.


 


(e) Cashless Exercise.
The Holder may elect to pay the Exercise Price by instructing the Company to withhold a number of Warrant Shares then issuable
upon exercise of this Warrant with an aggregate Fair Market Value as of the date of the Exercise Notice equal to the Aggregate
Exercise Price. In the event of any withholding of Warrant Shares pursuant to this Section 1(e) where the number of shares whose
value is equal to the Aggregate Exercise Price is not a whole number, the number of shares withheld by or surrendered to the Company
shall be rounded up to the nearest whole share and the Company shall make a cash payment to the Holder (by delivery of a certified
or official bank check or by wire transfer of immediately available funds) based on the incremental fraction of a share being so
withheld by or surrendered to the Company in an amount equal to the product of (x) such incremental fraction of a share being so
withheld or surrendered multiplied by (y) the Fair Market Value per Warrant Share as of the date of the Exercise Notice.


 


2. ADJUSTMENT OF
EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant Shares shall be adjusted from time
to time as follows:


 


(a) Voluntary Adjustment
By Company. The Company may at any time during the term of this Warrant, with the prior written consent of the Required Holders,
reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of
the Company.


 


(b) Adjustment Upon
Subdivision or Combination of Common Stock. If the Company at any time on or after the Issuance Date subdivides (by any stock
split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater
number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number
of Warrant Shares will be proportionately increased. If the Company at any time on or after the Issuance Date combines (by combination,
reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares,
the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant
Shares will be proportionately decreased. Any adjustment under this Section 2(b) shall become effective at the close of business
on the date the subdivision or combination becomes effective.


 


 


 


 






    	 	3	 



     


    

 


(c) Adjustment Upon
Reorganization, Reclassification, Consolidation or Merger. In the event of any (i) capital reorganization of the Company, (ii)
reclassification of the stock of the Company (other than a change in par value or from par value to no par value or from no par
value to par value or as a result of a stock dividend or subdivision, split-up or combination of shares), (iii) consolidation or
merger of the Company with or into another Person, (iv) sale of all or substantially all of the Company's assets to another Person
or (v) other similar transaction, in each case which entitles the holders of Common Stock to receive (either directly or upon subsequent
liquidation) stock, securities or assets with respect to or in exchange for Common Stock, each Warrant shall, immediately after
such reorganization, reclassification, consolidation, merger, sale or similar transaction, remain outstanding and shall thereafter,
in lieu of or in addition to (as the case may be) the number of Warrant Shares then exercisable under this Warrant, be exercisable
for the kind and number of shares of stock or other securities or assets of the Company or of the successor Person resulting from
such transaction to which the Holder would have been entitled upon such reorganization, reclassification, consolidation, merger,
sale or similar transaction if the Holder had exercised this Warrant in full immediately prior to the time of such reorganization,
reclassification, consolidation, merger, sale or similar transaction and acquired the applicable number of Warrant Shares then
issuable hereunder as a result of such exercise (without taking into account any limitations or restrictions on the exercisability
of this Warrant); and, in such case, appropriate adjustment (in form and substance satisfactory to the Holder) shall be made with
respect to the Holder’s rights under this Warrant to insure that the provisions of this Section 2 hereof shall thereafter
be applicable, as nearly as possible, to this Warrant in relation to any shares of stock, securities or assets thereafter acquirable
upon exercise of this Warrant (including, in the case of any consolidation, merger, sale or similar transaction in which the successor
or purchasing Person is other than the Company, an immediate adjustment in the Exercise Price to the value per share for the Common
Stock reflected by the terms of such consolidation, merger, sale or similar transaction, and a corresponding immediate adjustment
to the number of Warrant Shares acquirable upon exercise of this Warrant without regard to any limitations or restrictions on exercise,
if the value so reflected is less than the Exercise Price in effect immediately prior to such consolidation, merger, sale or similar
transaction). The provisions of this Section 2(c) shall similarly apply to successive reorganizations, reclassifications, consolidations,
mergers, sales or similar transactions. The Company shall not effect any such reorganization, reclassification, consolidation,
merger, sale or similar transaction unless, prior to the consummation thereof, the successor Person (if other than the Company)
resulting from such reorganization, reclassification, consolidation, merger, sale or similar transaction, shall assume, by written
instrument substantially similar in form and substance to this Warrant and satisfactory to the Holder, the obligation to deliver
to the Holder such shares of stock, securities or assets which, in accordance with the foregoing provisions, such Holder shall
be entitled to receive upon exercise of this Warrant. Notwithstanding anything to the contrary contained herein, with respect to
any corporate event or other transaction contemplated by the provisions of this Section 2(c), the Holder shall have the right to
elect prior to the consummation of such event or transaction, to give effect to the exercise rights contained in Section 1 instead
of giving effect to the provisions contained in this Section 2(c) with respect to this Warrant.


 


3. NONCIRCUMVENTION.
The Company hereby covenants and agrees that the Company will not, by amendment of its Articles of Incorporation or Bylaws, or
through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities,
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will
at all times in good faith carry out all of the provisions of this Warrant and take all action as may be required to protect the
rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any
shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all
such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the Loan Warrants are outstanding,
take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the
purpose of effecting the exercise of the Loan Warrants, 100% of the number of shares of Common Stock as shall from time to time
be necessary to effect the exercise of the Loan Warrants then outstanding.


 


 


 


 


 






    	 	4	 



     


    

 


4. WARRANT HOLDER
NOT DEEMED A STOCKHOLDER. The Holder, solely in its capacity as a holder of this Warrant, shall not be entitled to vote or
receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this
Warrant be construed to confer upon the Holder, solely in its capacity as the Holder of this Warrant, any of the rights of a stockholder
of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock,
reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription
rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which it is then entitled to receive upon the due
exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the
Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company.



 



5. REISSUANCE OF
WARRANTS.


 


(a) Transfer of Warrant.
If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith
issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 5(d)), registered as the Holder may request,
representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number
of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 5(d)) to the Holder
representing the right to purchase the number of Warrant Shares not being transferred.


 


(b) Lost, Stolen or
Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder
to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall
execute and deliver to the Holder a new Warrant (in accordance with Section 5(d)) representing the right to purchase the Warrant
Shares then underlying this Warrant.


 


(c) Exchangeable for
Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company,
for a new Warrant or Warrants (in accordance with Section 5(d)) representing in the aggregate the right to purchase the number
of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of
such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Loan
Warrants for fractional Warrant Shares shall be given.


 


(d) Issuance of New
Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i)
shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase
the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 5(a) or Section
5(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other
new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant),
(iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv)
shall have the same rights, terms and conditions as this Warrant.


 


6. REPRESENTATIONS
AND WARRANTIES OF THE HOLDER. As of the Issuance Date and upon delivery of each Exercise Notice, the Holder represents and
warrants to the Company as follows:


 


(a) No Public Sale
or Distribution. The Holder is acquiring this Warrant, and when issued in accordance with the terms of this Warrant, the Warrant
Shares, in the ordinary course of its business for its own account and not with a view towards, or for resale in connection with,
the public sale or distribution thereof, except pursuant to sales registered or exempted under the Securities Act of 1933, as amended
(the “Securities Act”). The Holder does not presently have any agreement or understanding, directly or indirectly,
with any Person to distribute any of the Securities.


 


 


 


 






    	 	5	 



     


    

 


(b) Holder Status
and Experience. The Holder is, and on each date on which the Holder acquires any Warrant Shares it will be, an “accredited
investor” as that term is defined in Rule 501(a) of Regulation D. The Holder, either alone or together with its representatives,
has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits
and risks of the investment in the Securities, and has so evaluated the merits and risks of such investment. The Holder is able
to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such
investment.


 



(c) Information.
The Holder and its advisors, if any, have been furnished with all materials relating to the business finances and operations of
the Company and materials relating to the offer and issuance of the Securities that have been requested by the Holder. The Holder
and its advisors, if any, have been afforded the opportunity to ask questions of the Company and receive answers from the Company
concerning the terms and conditions of the offering of the Securities, the merits of investing in the Securities and the business,
finances and operations of the Company. Neither such inquiries nor any other due diligence investigations conducted by the Holder
or is advisors, if any, or its representatives shall modify, amend or affect the Holder’s right to rely on the Company’s
representations and warranties contained herein. The Holder understands that its investment in the Securities involves a high degree
of risk. The Holder has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment
decision with respect to its acquisition of the Securities.


 


(d) Transfer or Resale.
The Holder understands that: (i) the Securities are “restricted securities” under applicable securities laws and have
not been and are not being registered under the Securities Act or any state securities laws, and may not be offered for sale, sold,
assigned or transferred unless (A) subsequently registered thereunder, (B) the Holder shall have delivered to the Company (if requested
by the Company) an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Securities to be
sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) the
Holder provides the Company with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule
144 or Rule 144A promulgated under the Securities Act (or a successor rule thereto) (collectively, “Rule 144”);
(ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and further,
if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom
the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with
some other exemption under the Securities Act or the rules and regulations of the Securities and Exchange Commission thereunder;
and (iii) neither the Company nor any other Person is under any obligation to register the Securities under the Securities Act
or any state securities laws or to assist the Holder to comply with the terms and conditions of any exemption thereunder. Notwithstanding
the foregoing, the Securities may be pledged in connection with a bona fide margin account with a FINRA registered broker/dealer
or other loan or financing arrangement with an accredited investor secured by the Securities and such pledge of Securities shall
not be deemed to be a transfer, sale or assignment of the Securities hereunder, and if the Holder effects such a pledge of Securities
it shall not be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant
to this Agreement. The Holder understands that the Warrant Shares shall bear such restrictive legend as required by the Company.
THE HOLDER UNDERSTANDS THAT THE WARRANT SHARES WILL BE SUBJECT TO THE TERMS AND PROVISIONS OF (A) THE ARTICLES OF INCORPORATION
OF THE COMPANY, AS AMENDED FROM TIME TO TIME, INCLUDING, WITHOUT LIMITATION, THE CERTIFICATES OF DESIGNATION RELATING TO ALL SERIES
OF PREFERRED STOCK, AND THE RELATIVE RIGHTS, PREFERENCES, RESTRICTIONS, DESIGNATIONS, QUALIFICATIONS AND PRIVILEGES SET FORTH THEREIN
AND IMPOSED THEREON AND UPON THE HOLDERS THEREOF, AND (B) THE BYLAWS OF THE COMPANY, AS AMENDED FROM TIME TO TIME, INCLUDING, WITHOUT
LIMITATION, A REDEMPTION RIGHT IN FAVOR OF THE COMPANY, TO ALL OF WHICH TERMS AND PROVISIONS THE HOLDER, BY ACCEPTANCE HEREOF,
ASSENTS.


 


(e) Reliance on Exemptions.
The Holder understands that the Securities are being offered and issued to it in reliance on specific exemptions from the registration
requirements of applicable securities laws and that the Company is relying in part upon the truth and accuracy of, and the Holder’s
compliance with, the representations and warranties of the Holder set forth herein in order to determine the availability of such
exemptions and eligibility of the Holder to acquire the Securities.


 


 


 


 






    	 	6	 



     


    

 


(f) Bad Actor.
Neither the Holder, nor any of its directors, executive officers, general partners, managers, managing members or beneficial owners
of 20% of the Holder’s outstanding voting equity securities, calculated on the basis of voting power, is subject to any “Bad
Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) promulgated under the Securities Act (a “Disqualification
Event”), except for a Disqualification Event (i) contemplated by Rule 506(d)(2) promulgated under the Securities Act,
and (ii) a description of which has been furnished in writing to the Company before the date hereof.


 


(g) FINRA Lists.
The Holder is not included in the list of entities barred by the Financial Industry Regulatory Authority.


 


(h) Blocked Persons
and Sanctions. Neither the Holder nor any director, officer, employee, agent, affiliate or other Person associated with or
acting on behalf of the Holder is, or is directly or indirectly owned or controlled by, a Person that is restricted from doing
business under the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism
Act of 2001, H.R. 3162, Public Law 107-56, as amended (commonly known as the “USA Patriot Act”), or any executive order,
including, without limitation, Executive Order Number 13224 on Terrorism Financing, effective September 24, 2001, and the regulations
promulgated pursuant thereto or currently the subject or the target of any sanctions administered or enforced, or any relevant
lists maintained, by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department
of the Treasury or the U.S. Departments of State or Commerce and including, without limitation, the designation as a “Specially
Designated National” or on the “Sectoral Sanctions Identifications List”, collectively “Blocked Persons”),
the United Nations, the European Union, Her Majesty’s Treasury, the North Atlantic Treaty Organization, the Financial Action
Task Force on Money Laundering of Organization for Economic Cooperation and Development, or any other relevant sanctions authority
(collectively, “Sanctions Laws”); neither the Holder, nor any director, officer, employee, agent, affiliate
or other Person associated with or acting on behalf of the Holder is located, organized or resident in a country or territory that
is the subject or target of a comprehensive embargo or Sanctions Laws prohibiting trade with the country or territory, including,
without limitation, Crimea, Cuba, Iran, North Korea, Sudan and Syria (each, a “Sanctioned Country”); neither
the Holder nor any director, officer, employee, agent, affiliate or other Person associated with or acting on behalf of the Holder,
acting in any capacity in connection with the operations of the Holder, conducts any business with or for the benefit of any Blocked
Person or engages in making or receiving any contribution of funds, goods or services to, from or for the benefit of any Blocked
Person, or deals in, or otherwise engages in any transaction relating to, any property or interests in property blocked or subject
to blocking pursuant to any applicable Sanctions Laws. The Holder has not knowingly engaged in and is not now knowingly engaged
in any dealings or transactions with any Person that at the time of the dealing or transaction is or was the subject or the target
of Sanctions Laws or with any Sanctioned Country.


 


(i) Foreign
Political Figure. Neither the Holder nor any of its directors, executive officers, general partners, managers, managing members
or beneficial owners is a senior foreign political figure, any member of a senior foreign political figure’s immediate family
or any close associate of a senior foreign political figure.


 


7. NOTICES.


 


(a) Whenever
notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance with
Section 9.01 of the Loan Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant
to this Warrant, including in reasonable detail a description of such action and the reason therefor. Without limiting the generality
of the foregoing, the Company will give written notice to the Holder immediately upon any adjustment of the Exercise Price, setting
forth in reasonable detail, and certifying, the calculation of such adjustment.


 


(b) In
the event:


 


(i)that the Company
shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon exercise
of the Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution, to vote at a meeting
(or by written consent), to receive any right to subscribe for or purchase any shares of capital stock of any class or any other
securities, or to receive any other security; or


 


 


 


 






    	 	7	 



     


    

 





 


(ii)of any capital
reorganization of the Company, any reclassification of the Common Stock of the Company, any consolidation or merger of the Company
with or into another Person, or sale of all or substantially all of the Company's assets to another Person; or


 


(iii)of the voluntary
or involuntary dissolution, liquidation or winding-up of the Company;


 


then, and in each such
case, the Company shall send or cause to be sent to the Holder at least 20 Business Days prior to the applicable record date or
the applicable expected effective date, as the case may be, for the event, a written notice specifying, as the case may be, (A)
the record date for such dividend, distribution, meeting or consent or other right or action, and a description of such dividend,
distribution or other right or action to be taken at such meeting or by written consent, or (B) the effective date on which such
reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up is proposed to take place,
and the date, if any is to be fixed, as of which the books of the Company shall close or a record shall be taken with respect to
which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon exercise of the
Warrant) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities
or other property deliverable upon such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation
or winding-up, and the amount per share and character of such exchange applicable to the Warrant and the Warrant Shares.


 


8. AMENDMENT AND
WAIVER. Except as otherwise provided herein, the provisions of this Warrant and the other Loan Warrants may be amended or waived
and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if
the Company has obtained the written consent of the Required Holders and any amendment, waiver or action made in conformity with
the provisions of this Section 8 shall be binding on all holders of Loan Warrants and the Company. The Holder acknowledges and
agrees that by operation of this Section 8, the Required Holders will have the right and power to amend this Warrant and the other
Loan Warrants, including, without limitation, the power to diminish or eliminate all rights of the Holder under this Warrant.


 


9. GOVERNING LAW;
JURISDICTION; JURY TRIAL. This Warrant shall be governed by and construed and enforced in accordance with, and all questions
concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of
the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of
New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of
New York. The Company and the Holder each hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and each hereby irrevocably waives, and agrees not to assert in
any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. The
Company and the Holder each hereby irrevocably waives personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof to the respective address set forth in Section 9.01 of the Loan Agreement
or otherwise designated in writing pursuant to Section 9.01 of the Loan Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any manner permitted by law. THE COMPANY AND THE HOLDER EACH HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE,
AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS
WARRANT.


 


10. CONSTRUCTION;
HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against
any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or
affect the interpretation of, this Warrant.


 


 


 


 






    	 	8	 



     


    

 





11. REMEDIES, OTHER
OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition to all
other remedies available under this Warrant and the other Loan Documents (as defined in the Loan Agreement), at law or in equity
(including, without limitation, a decree of specific performance and/or other injunctive relief), and nothing herein shall limit
the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company
acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at
law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach, the holder of this
Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach.


 


12. TRANSFER.
This Warrant and the Warrant Shares may be offered for sale, sold, transferred, pledged or assigned without the consent of the
Company, subject to compliance with all applicable federal and state securities laws.


 


13. SEVERABILITY.
If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material
change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability
of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties
or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good
faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which
comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).


 


14. CERTAIN DEFINITIONS.
For purposes of this Warrant, the following terms shall have the following meanings:


 


(a) “Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed.


 


(b) “Common
Stock” means (i) the Company’s shares of common stock, par value $0.001 per share, and (ii) any stock capital into
which such Common Stock shall have been changed or any stock capital resulting from a reclassification, reorganization or reclassification
of such Common Stock.


 


(c) “Expiration
Date” means the date 60 months after the Issuance Date or, if such date falls on a day other than a Business Day or a
Trading Day (such day, a “Holiday”), the next day that is not a Holiday.


 


(d) “Fair Market
Value” means, as of any particular date, the arithmetic average over the 20 consecutive Trading Days ending on the Trading
Day immediately prior to the day as of which “Fair Market Value” is being determined of, as applicable, (i) the volume
weighted average of the closing sales prices of the Common Stock for such day on all domestic securities exchanges on which the
Common Stock may at the time be listed; (ii) if there have been no sales of the Common Stock on any such exchange on any such
day, the average of the highest bid and lowest asked prices for the Common Stock on all such exchanges at the end of such day;
(iii) if on any such day the Common Stock is not listed on a domestic securities exchange, the closing sales price of the Common
Stock as quoted on the Principal Market; or (iv) if there have been no sales of the Common Stock on Principal Market on any such
day, the average of the highest bid and lowest asked prices for the Common Stock quoted on the Princial Market at the end of such
day. If at any time the Common Stock is not listed on any domestic securities exchange or quoted on the Principal Market or similar
quotation system or association, the “Fair Market Value” of the Common Stock shall be the fair market value per share
as determined jointly by the Company and the Holder; provided, that if the Company and the Holder are unable to agree on
the fair market value per share of the Common Stock within a reasonable period of time (not to exceed 20 days from the Company’s
receipt of the Exercise Notice), such fair market value shall be determined by a nationally recognized investment banking, accounting
or valuation firm jointly selected by the Company and the Holder. The determination of such firm shall be final and conclusive,
and the fees and expenses of such firm shall be borne by the Company. All such determinations shall be appropriately adjusted
for any stock dividend, stock split, stock combination, reclassification or other similar transaction during the applicable calculation
period.


 


 


 


 






    	 	9	 



     


    

 


(e) “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and a government or any department or agency thereof.


 


(f) “Principal
Market” means the OTCQX.


 


(g) “Required
Holders” means the holders of the Loan Warrants representing at least a majority of the shares of Common Stock underlying
all of the Loan Warrants then outstanding.


 


(h) “Trading
Day” means any day on which the Common Stock is traded or qualified for quotation on the Principal Market, or, if the
Principal Market is not the principal trading market for the Common Stock on such day, then on the principal securities exchange
or securities market on which the Common Stock is then traded or qualified for quotation.


 


[Signature Page Follows]


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 






    	 	10	 



     


    

 


IN WITNESS WHEREOF,
the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.


 


	 	
         

        

        

        MEDICINE MAN TECHNOLOGIES, INC.

         

        By: /s/ Justin Dye                                                         

        Name: Jusin Dye

        Title: Chief Executive Officer

         



  


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 






    	 	11	 



     


    

 


EXHIBIT A


 


FORM OF EXERCISE NOTICE


TO BE EXECUTED BY THE REGISTERED HOLDER
TO EXERCISE THIS

WARRANT TO PURCHASE COMMON STOCK


MEDICINE MAN TECHNOLOGIES, INC.


 


The undersigned holder
hereby exercises the right to purchase ____________ shares of Common Stock (“Warrant Shares”) of Medicine Man
Technologies, Inc., a Nevada corporation d/b/a/ Schwazze (the “Company”), evidenced by the attached Warrant
to Purchase Common Stock (the “Warrant”). Capitalized terms used herein and not otherwise defined shall have
the respective meanings set forth in the Warrant.


 


1. Payment of Exercise
Price. The holder shall pay the Aggregate Exercise Price in the sum of $__________________ to the Company in accordance with
the terms of the Warrant. Payment is to be paid [ ] in cash or [ ] pursuant to Section 1(e) of the Warrant.


 


2. Delivery of Warrant
Shares. The Company shall deliver to the holder ____________ Warrant Shares in accordance with the terms of the Warrant.


 


3. Representations
and Warranties. The representations and warranties set forth in Section 6 of the Warrant are true and correct in all respects
with the same effect as though such representations and warranties had been made as of the date of this Exercise Notice.


 


Please issue the Warrant Shares in the
following name and to the following account:


 


	Issue to:	 
	 	 
	 	 


 


	Facsimile Number and Electronic Mail:	 
	 	 
	Authorization:	 
	 	 
	By:	 
	 	 
	Title:	 
	 	 
	Dated:	 
	 	 
	Broker Name:	 
	 	 
	Broker DTC #:	 
	 	 
	Broker Telephone #:	 
	 	 
	Account Number:	 
	  (if electronic book entry transfer)	 
	 	 
	Transaction Code Number:	 
	  (if electronic book entry transfer)	 


 


 


 


 


 






    	 	12	 



     


    

 


ACKNOWLEDGMENT


 


The Company hereby acknowledges this Exercise
Notice and hereby directs the Transfer Agent to issue the above indicated number of shares of Common Stock.


 


	 	
         

        

        

        MEDICINE MAN TECHNOLOGIES, INC.

         

        By: _________________________

               Name:

               Title:



 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 






    	 	13